Genecast Biotechnology announced the raising of￥1280 Million in Series B funding from the lead investor THG Ventures and co-investors Loyal Valley Capital, COWINVC, Yahui Precision Medical Fund and Zehou Capital.

“Genecast Biotechnology is dedicated to becoming a leader in improving the quality life for cancer patients. We endeavor to improve our research capacity in a competitive environment while leading and staying ahead of the industry. We will devote to tumor precision treatment and hope to bring great value to more cancer patients to this industry in the future” said Bo Du, Chief Executive Officer of Genecast Biotechnology. 

Through awarded funding from the Series B financing, Mr. Du mentioned that Genecast will continuously focus on scientific/clinic research and channel expansion.